precisionmedicineonline22h
BRCA1/2 Mutations Aren't Equal: Researchers Push for Reduced Penetrance Pathogenic Variant Category
Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...
precisionmedicineonline17h
Syndax's Revuforj Garners FDA Approval for Refractory KMT2A-Altered Acute Leukemia
NEW YORK – The US Food and Drug Administration on Friday approved Syndax Pharmaceuticals' Revuforj (revumenib) as a treatment for adult and pediatric patients one year and older with relapsed or ...